Short answer
Fulgent Genetics, Inc. (FLGT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $90M (up 7.5% year over year) with net income of −$13M.
Q3 2026 key financials · XBRL
- Revenue
- $90M
- +7.5% YoY · +5.9% QoQ
- Net income
- −$13M
- −99.0% YoY · +55.5% QoQ
- Operating margin
- -24.9%
- Gross margin
- 35.3%
Source: XBRL data from the Fulgent Genetics, Inc. (FLGT) Q3 2026 10-Q on SEC EDGAR. USD.
Fulgent Genetics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $90.4M, up $6.3M, or 8% YoY
- Gross margin 35% vs 42% YoY, operating loss $22.5M vs $15.4M
- Best segment anatomic pathology: revenue $40.9M, up $14.9M YoY
- Worst segment precision diagnostics: revenue $41.8M, down $8.9M YoY
- Cash resources $652.4M, operating cash flow $92.6M, including $112.3M tax refund; stock repurchases $64.1M YTD
- Outlook: largest-customer revenue decline, billing-transition collection delays, rising clinical-trial spending and gross-margin uncertainty
Risk Factors
- No material risk-factor changes from 2025 10-K, including no newly added quarterly risk
- Billing-system transition: processing backlogs and collection delays may reduce collections, gross margin, liquidity, and results
- Legal investigations and audits: unfavorable outcomes remain uncertain, with potential defense costs, settlements, management diversion, and reputational harm
- Largest-customer concentration: customer insourcing continues reducing precision-diagnostics revenue during 2026
- Liquidity dependence: $112.3 million IRS refund drove operating cash flow, while excluding it operations used approximately $19.8 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Fulgent Genetics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.